Anika Therapeutics Reports Strong Q2 2026 Performance with Revenue Growth, Margin Expansion
Anika Therapeutics reported robust financial performance in the second quarter of 2026, driven by strong international demand for its products CINGAL and MONOVISC. The company achieved a record commercial channel revenue growth of 17%, while gross margins expanded to 65% due to lean manufacturing improvements that doubled throughput on key production lines. The firm also experienced significant growth in regenerative solutions through the Integrity platform, particularly with larger product sizes addressing more patient anatomies. Leveraging its partnership with Johnson & Johnson (J&J), Anika saw a 14% increase in OEM revenue despite U.S. pricing challenges. The company reduced general and administrative expenses by 30%, as well as stock-based compensation costs by 28%, to prioritize shareholder value. Looking ahead, Anika raised its full-year 2026 revenue guidance to reflect sustained international momentum and strong OEM performance. Adjusted EBITDA margin expectations were also increased significantly due to ongoing manufacturing efficiencies. The company anticipates positive free cash flow in the second half of 2026 as accounts receivable convert into cash.
Topics: earnings margin expansion operational efficiency revenue growth